2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine has been researched along with ALS - Amyotrophic Lateral Sclerosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cleveland, DW; Hirano, A; Horiuchi, S; Kato, M; Kato, S; Liu, J; Nagai, R; Nakano, I; Nakashima, K; Ohama, E; Shibata, N; Takikawa, M | 1 |
1 other study(ies) available for 2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Advanced glycation endproduct-modified superoxide dismutase-1 (SOD1)-positive inclusions are common to familial amyotrophic lateral sclerosis patients with SOD1 gene mutations and transgenic mice expressing human SOD1 with a G85R mutation.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Animals; Arginine; Female; Glycation End Products, Advanced; Histocytochemistry; Humans; Immunohistochemistry; Inclusion Bodies; Lysine; Male; Mice; Mice, Transgenic; Microscopy, Electron; Microscopy, Immunoelectron; Middle Aged; Mutation; Norleucine; Pyrroles; Superoxide Dismutase; Superoxide Dismutase-1 | 2000 |